Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Millennium BioTherapeutics Inc.

Division of Takeda Pharmaceutical Co. Ltd.

Latest From Millennium BioTherapeutics Inc.

Takeda: 12 NMEs Poised To Launch In Five Years, And Deliver $10 Bn In Peak Sales

The Japanese pharma held its first investor day in New York, outlining the company's strategy to deliver long-term growth through a newly energized oncology, gastrointestinal and rare disease pipeline.

Business Strategies Cancer

Risk Sharing the Millennium Way

Previous deals, such as those with Bayer and Monsanto, showcased Millennium Pharmaceuticals' technology integration capabilities and allowed it to leverage the value of its platform. It is now becoming more focused on using external relationships and acquisitions to forward integrate and build a product pipeline. Via a series of agreements with Aventis signed in June valued at $450 million, Millennium expects to build nothing less than the world's premier franchise in inflammation. And the agreements, including a tech transfer deal and a technology development deal along with the inflammation drug development collaboration and an equity investment by Aventis, appear to provide Millennium a way to fund drug development risk by leveraging its technology.
BioPharmaceutical Strategy

Chutzpah: Millennium Takes on Diagnostics

Millennium is turning its business development skills on diagnostics, promising to create a high margin business in what has been a price-cutter's paradise. Its advantage: using the discovery infrastructure built at Millennium and financed by drug companies for their deals with Millennium on drug discovery. All Millennium claims that it needs to make diagnostics pay (it hasn't for the vast majority of other diagnostics start-ups) is funding from diagnostics companies and drug firms interested in pursuing pharmacogenomics. Its major competition, the joint venture between SmithKline and Incyte called diaDexus, is skeptical that diagnostic firms, which have hitherto spent their R&D budgets on developing new instrument platforms, not the high risk hunt for new diagnostic markers, will change their tune now, and spend more on biological research than they ever have before by signing deals with Millennium. But Millennium is convinced that without the kind of new, important and expensive diagnostics it can discover with its biotech platform, such traditional diagnostic firms will continue to merely grind their profitability down in price wars.
BioPharmaceutical Medical Device

Agricultural Opportunities

Millennium's recent blockbuster deal with Monsanto isn't in healthcare--it's in agriculture. Now other drug-oriented biotechs are considering whether they too can leverage their discovery assets this way. Some firms believe their technologies are directly translatable; others say ag companies can't afford to pay for the methods. The big question: whether to do exclusive deals.
BioPharmaceutical Consumer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Ronald M Lindsay, PhD, VP, Preclinical Research
    Kevin Starr, VP, Fin.
  • Contact Info
  • Millennium BioTherapeutics Inc.
    Phone: (617) 374-9480
    640 Memorial Dr., 3rd Fl.
    Cambridge, MA 02139